ClinicalTrials.gg
RecruitingNCT07111832Updated Dec 18, 2025

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

A Phase 3 interventional study of SHR-A1811 for Injection and SHR-1316 Injection in PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
39th of 235
400 · median 90
Started
2025
with 27 others
Phase 3
48 of 252
19 open now
Primary completion
2028-03
later than 121 of 152 live
Registered
212th of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 39th largest by planned enrollment of the 235 interventional ones that give a count, is one of 28 that started in 2025, is one of 48 in phase 3, reaches primary completion later than 121 of the 152 other live ones, and was the 212th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).

03

Conditions studied

  • PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years old (including both ends), female.
  2. confirmed locally recurrent unresectable or triple-negative breast cancer.
  3. Expected survival ≥ 12 weeks.
  4. Have adequate renal and hepatic function.
  5. Patients voluntarily joined the study and signed the .

Exclusion criteria

Exclusion Criteria:

  1. Patients with active central nervous system (CNS) who have not undergone surgery or radiotherapy.
  2. Have other within the past 5 years.
  3. Presence with uncontrollable third space effusion.
  4. Have undergone other anti-tumor treatment within 4 weeks before the first dose.
  5. A history of immunodeficiency.
  6. cardiovascular diseases.
  7. Known or suspected interstitial lung disease.
  8. Known hereditary or acquired bleeding tendency.
  9. Toxicities from prior anti-tumor therapy that have not recovered to ≤ Grade 1.
  10. Known to any of the study drugs or their , or a history of allergy to humanized monoclonal antibody products.
  11. Presence of other severe physical or mental disorders or clinically significant laboratory abnormalities.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    SHR-A1811 and SHR-1316 Group

    Drug: SHR-A1811 for Injection · Drug: SHR-1316 Injection

  • Active comparator
    Toripalimab and Nab-paclitaxel Group

    Drug: Toripalimab Injection · Drug: Paclitaxel for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Time frame: An average of 3 year.

Secondary outcomes

  1. Overall response (OS) rate evaluated by investigators

    Time frame: An average of 3 year.

  2. Clinical benefit rate (CBR) evaluated by investigators

    Time frame: An average of 3 year.

  3. Duration of response (DoR) evaluated by investigators

    Time frame: An average of 3 year.

  4. Progression-free survival on next-line therapy (PFS2) evaluated by investigators

    Time frame: An average of 3 year.

  5. Adverse events (AEs)

    Time frame: An average of 3 year.

  6. Serious adverse events (SAEs)

    Time frame: An average of 3 year.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Aug 20, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Dec 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07111832
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 20, 2025
Primary completion
Mar 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 18, 2025

Study contacts

Tingting Lei
Contact
tingting.lei.tl6@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Adebrelimab

Start the discussion